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sditor’s Note
ue to communication problems, several Letters to the
ditor were misplaced and were not published in a timely
ashion. We became aware of this recently when one of
he authors contacted us as to the publication status. We
ave gathered those letters together and are now pub-
ishing them in this issue. In general, we believe that the
etters and the replies are self explanatory. We apologize
or this delay.
he CHARM of a Paradox
he paradox in the CHARM (Candesartan in Heart Failure:
ssessment of Reduction in Mortality and Morbidity) study (1)
eeds to be explained if low brachial systolic pressure is perceived
y physicians as a contraindication to the use of arterial dilator
rugs such as nitrates, carvedilol, and candesartan in systolic heart
ailure. Meredith et al. (1) extended results of previous studies
AHeFT [African-American Heart Failure Trial (2)] and
OPERNICUS [Carvedilol Prospective Randomized Cumulative
urvival (3)]) in showing that an arterial vasodilator was at least as
ffective in trials of cardiac failure for improving outcomes in
atients with systolic blood pressure (SBP) 100 mm Hg (whose
eft ventricular ejection fraction averaged 25%) as in those with
ormal or high SBP and without appreciable risk of causing
ymptomatic hypotension.
The paradox arises from exclusive consideration of brachial
ather than central pressure (4) and from assuming that effects of
ilator drugs on high-resistance arterioles dominate over effects on
ow-resistance conduit arteries. Arterial vasodilator drugs such as
itroglycerin reduce wave reflection (5,6) and “trap” reflected
ressure waves in the peripheral circulation so that they do not
ummate with central systolic pressure, with this differentially
educed compared with brachial SBP (4,6). In patients with a low
eft ventricular ejection fraction and the ventricle contracting
eakly and acting (in engineering terms) as a “pressure source”
6,7), reduction in aortic and left ventricular systolic pressure leads
o increased left ventricular ejection from the heart (6,7). Such an
ncrease in stroke volume can maintain or increase SBP in patients
ith cardiac failure due to systolic dysfunction.
The paradox described by Meredith et al. (1) is explicable. It
xplains why drugs that dilate muscular arteries and reduce wave
eflection are very effective for reducing systolic pressure in
ypertension when the heart is contracting normally (i.e., as a flow
ource) (6,7) and for increasing cardiac output in patients with
eart failure when the heart’s contraction is weakened, and it acts
s a pressure source (6,7).
Consideration of blood pressure, cardiac output, and peripheral
esistance is insufficient to explain the function of the pulsating
eart and blood vessels. These comments are offered without any
riticism of the excellent work of Meredith et al. (1). pMichael F. O’Rourke, DSc, MD
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ardiac Resynchronization
n Mildly Symptomatic
eart Failure and
symptomatic Patients
read with interest the results of the REVERSE (REsynchroni-
ation reVErses Remodeling in Systolic left vEntricular dysfunc-
ion) trial in the paper by Linde et al. (1). The trial concluded that
ardiac resynchronization therapy, in combination with optimal
edical therapy, reduces the risk of heart failure hospitalization
nd improves ventricular structure and function in New York
eart Association functional class I and II patients with previous
eart failure symptoms. I think that it is worth noting that the
tudied population was composed of patients having significantly
rolonged QRS duration (average 156 ms) as well as quite severe
